The Efficacy and Safety of Ornithine Aspartic Acid Granules in NAFLD Against Silymarin Capsules

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine237 enrolled

Overview

This is a multicenter, randomized, double-blind, double-dummy, and positive control clinic trial which explores the efficacy and safety of ornithine aspartate granules in the treatment of non-alcoholic fatty liver disease against silymarin capsules. The hypothesis is that the ornithine aspartate granules have similar or better efficacy than the silymarin capsules.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

237

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

Ornithine aspartate granuleDRUG

Ornithine aspartate granules in the experimental arm.

Silymarin capsuleDRUG

Silymarin capsules in the active comparator arm.

Silymarin capsule simulantDRUG

Silymarin capsule simulant in the experimental arm.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Consistent with NAFLD diagnosis criteria, and during previous one month, the B-mode ultrasonography showed diffuse fatty liver and Fibroscan test showed that CAP value \> 248 db/m; * 2\. During previous one month, serum ALT level was higher than 1.5 times the upper limit of normal. * 3\. BMI is not more than 30 kg/m2. * 4\. Voluntary to participate in the research and signed a written informed consent to comply with the trial protocol. Exclusion Criteria: * 1\. Hereditary metabolic or autoimmune liver disease, hepatotropic and non-hepatotropic virus infection, drug/toxic/alcoholic/biliary liver injury, or any end-stage liver disease; fatty liver disease caused by one of the following reasons: total parenteral nutrition, inflammatory bowel disease, hypothyroidism, Cushing's syndrome, beta-lipoprotein deficiency and some insulin resistance (IR) related syndromes (lipid atrophic diabetes, Mauriac syndrome); * 2\. Hepatic or extrahepatic malignant tumors; * 3\. Severe heart failure or renal failure (serum creatinine \> 3mg/100mL); * 4\. Allergic constitution, or allergic to amino acid drugs or to ornithine aspartate and its constituents or to silymarin; * 5\. ALT or γ-glutamyl transpeptidase (γ-GT) are greater than 5 times the upper limit of normal, or total bilirubin (TBIL) \> 51 umol/L.; * 6\. Confirmed liver cirrhosis or Fibroscan test showed E value \> 12.5 kilopascal (KPa); * 7\. Triglyceride \> 5.6mmol/L; * 8\. Diabetes diagnosed for more than 5 years, combined with current insulin therapy or taking hypoglycemic drugs with poorly controlled condition (HbA1c \> 9%). * 9\. Women who are pregnant, nursing or preparing for pregnancy; * 10\. Suspected or confirmed excessive drinking (equivalent alcohol amount: male, \> 40g/d; female, \> 20g/d), or history of drug abuse; * 11\. Combined use of drugs with liver protection and anti-inflammatory effects, as well as any Chinese patent medicine, Chinese herbal medicine, or health products that may have liver protection or liver damage effects; * 12\. Taking weight-loss drugs or receiving weight-loss treatment; * 13\. Situations of inappropriate participation judged by researchers.

Locations (1)

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

The proportion of patients whose controlled attenuation parameter (CAP) value returned to normal or changed by more than 10%

Time frame: Assessed at 24 weeks

Secondary Outcomes

The changed degree of quality-of-life measured by the Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH

Time frame: Assessed at 4 weeks, 12 weeks, and 24 weeks

The proportion of patients whose alanine aminotransferase (ALT) level returned to normal or changed by more than 50%

Time frame: Assessed at 4 weeks, 12 weeks, and 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.